A Uniquely Holistic Biotech Investment Strategy
Our Integrated BioSci Investing approach allows us to capitalize innovation in the life science sector for our shareholders as we support the innovation that delivers hope to patients worldwide
Bargain Growth Biotech Investing
We invest in innovative small-cap growth biotech stocks that are trading at a discount to their intrinsic value (i.e., true worth). These stocks have the potential to increase multiple folds in the long-term.
Binary Event Forecasting
We predict the outcomes of biotech binary events (i.e., pivotal developments in a young biotech company that include a BIG data release and FDA approval). That edge positioned our portfolio with stocks that have the best chances of significant value appreciation in the future.
Medical/Scientific Integration with Investment/Finance
Our unique combination of expertise in medicine/science and investing/finance allows us to have a deep understanding of our portfolio companies. This gives us an edge in understanding both the science behind the lead drug and the financial health of our investments.
About Evergrowth BioHealthcare Capital
Evergrowth BioHealthcare Capital is a pioneering biotech hedge fund that invests in innovative life science companies.
Founded by a group of doctors, experts, private investors, and Dr. Harvey Tran, a Columbia University physician scientist with deep expertise in biotech investing who pioneered a new approach, Integrated BioSci Investing.
Poised to Outperform, Driven by An Expert Edge
Join us to experience the power of data and event-driven Integrated BioSci Investing!
Featured Investment Stories
Discover how our investment strategies have delivered outstanding results
BioTech Inc
Through strategic investment and expert guidance, we helped BioTech Inc achieve a breakthrough in drug development, resulting in a significant increase in market value
PharmaGen
By identifying a hidden gem in the biotech market, we positioned PharmaGen for rapid growth and a successful IPO